Axogen (AXGN) director gains 14,150 shares from RSU vesting

Rhea-AI Filing Summary

TYNDALL JOSEPH A. reported acquisition or exercise transactions in this Form 4 filing.

Axogen, Inc. director Joseph A. Tyndall reported the vesting of 14,150 restricted stock units on June 19, 2026, which were settled into 14,150 shares of common stock. Each restricted stock unit represented a right to receive one share upon vesting, reflecting an annual equity grant for board service valued at $150,000 on the grant date. This filing shows a compensation-related equity award vesting, not an open-market stock purchase or sale.

Insider Trade Summary

14,150 shares exercised/converted

Mixed 2 txns

Insider TYNDALL JOSEPH A.

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	14,150	$0.00	--
Exercise	Common Stock	14,150	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 14,150 shares (Direct, null)

Footnotes (1)

1. This reflects the number of restricted stock units that vested June 19, 2026. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

Key Figures

RSUs vested: 14,150 units Shares acquired: 14,150 shares Equity grant valuation: $150,000 +2 more

5 metrics

RSUs vested 14,150 units Restricted stock units vested on June 19, 2026

Shares acquired 14,150 shares Common stock received upon RSU vesting

Equity grant valuation $150,000 Annual director equity grant value as of grant date

Transactions acquiring shares 2 transactions Non-derivative and derivative entries related to RSU exercise

Derivative exercises 1 exercise, 14,150 shares Exercise/conversion of restricted stock units into common stock

Key Terms

Restricted Stock Units, contingent right, Annual equity grant, derivative security

4 terms

Restricted Stock Units financial

"This reflects the number of restricted stock units that vested June 19, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."

Annual equity grant financial

"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TYNDALL JOSEPH A.

(Last) (First) (Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA FLORIDA 32615

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/19/2026		M		14,150(1)	A	$0	14,150	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	06/19/2026		M		14,150		(3)	(3)	Common Stock	14,150	$0	0	D

Explanation of Responses:

1. This reflects the number of restricted stock units that vested June 19, 2026.

2. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

3. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

Remarks:

	/s/ Marc Began as attorney-in-fact for Joseph A. Tyndall	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Axogen (AXGN) report for Joseph A. Tyndall?

Axogen reported that director Joseph A. Tyndall acquired 14,150 shares of common stock through the vesting of 14,150 restricted stock units on June 19, 2026. This was a compensation-related equity award, not an open-market trade.

How many Axogen (AXGN) shares vested for the director in this Form 4?

A total of 14,150 restricted stock units vested for Joseph A. Tyndall, converting into 14,150 shares of Axogen common stock. The units were part of his annual equity compensation for serving on the company’s board of directors.

Was the Axogen (AXGN) Form 4 transaction a stock sale or a grant vesting?

The Form 4 reflects a grant vesting, not a stock sale. Restricted stock units previously granted to director Joseph A. Tyndall vested and were settled into common shares as part of his annual equity compensation for board service.

What was the valuation of the Axogen (AXGN) director’s equity grant?

The annual equity grant for Joseph A. Tyndall was based on a valuation of $150,000 as of the grant date. The number of restricted stock units, 14,150, was determined using this grant-date valuation and vested one year after the grant.

When did the Axogen (AXGN) restricted stock units vest for the director?

The restricted stock units vested on June 19, 2026, which was the one-year anniversary of the grant date. On that date, 14,150 restricted stock units converted into an equal number of Axogen common shares for director Joseph A. Tyndall.